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Purpose: Carotid angioplasty and stenting (CAS) is being evaluated as an alternative to carotid endarterectomy (CEA) for
treatment of severe carotid artery stenosis. Because CAS does not require general anesthesia and is less traumatic, it might
be especially advantageous in older patients, but data comparing these 2 treatment methods in older patients are scarce.
Methods: The periprocedural complication rates in 53 patients aged 75 years or older who had undergone protected CAS
between June 2001 and April 2004 were compared with those in a group of 110 patients aged 75 years or older who had
undergone CEA between January 1997 and December 2001, before widespread introduction of CAS procedures at our
institution. All patients were evaluated by a neurologist both before and after surgery. According to the criteria set forth
by the large trials the occurrence of minor, major, or fatal stroke, and myocardial infarction within 30 days was
determined.
Results: The demographic characteristics and indications for an intervention were similar in both treatment groups.
Thirty patients (57%) in the CAS group had symptomatic carotid stenosis, compared with 69 patients (63%) in the CEA
group. In neither group was there any fatal stroke or myocardial infarction. The 30-day stroke rate was significantly
higher in the CAS group (4 minor, 2 major strokes; 11.3%) than in the CEA group (no minor, 2 major strokes; 1.8%; P
< .05). Although the 30-day major stroke rate between CAS and CEA groups was comparable (3.8% vs 1.8%; P  0.6),
this effect was mainly attributable to a significantly higher rate of minor stroke in the CAS group (7.5% vs 0%; P < .05).
Conclusion: Despite the use of cerebral protection devices the neurologic complication rate in patients aged 75 years and
older associated with CAS was significantly higher than with CEA performed by highly skilled surgeons at our academic
institution. Although this finding is mainly based on a significantly higher rate of minor stroke in the CAS group, the
common practice of preferentially submitting older patients to CAS is questionable, and should be abandoned until the
results of further randomized trials are available. ( J Vasc Surg 2004;40:945-51.)In the last 2 decades several landmark studies on carotid
endarterectomy (CEA) have been published that have clar-
ified the benefits and risks of the procedure. In 1991 the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET) unequivocally demonstrated that CEA is
effective for preventing stroke in patients with symptomatic
internal carotid artery disease (CAD) of 70% percent or
greater if it is performed in high-volume centers by highly
skilled surgeons in patients with low complication rates.1
Similar results were found in patients with symptomatic
high-grade CAD enrolled in the European Carotid Surgery
Trial (ECST)2 and the Veterans Affairs Cooperative Symp-
tomatic Carotid Stenosis Trial.3 Although the role of sur-
gery in asymptomatic CAD has been controversial, 2 large
trials have demonstrated that CEA is superior to medical
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doi:10.1016/j.jvs.2004.08.022treatment in prevention of stroke in patients with asymp-
tomatic high-grade CAD.4,5
A key feature of these large surgical trials was the ability
of the participating centers to maintain low rates of periop-
erative complications. This was mainly achieved by carefully
selecting surgeons with extensive expertise and by exclud-
ing patients at high risk with concomitant medical condi-
tions, such as coronary artery disease or valvular heart
diseases, cardiac arrhythmias, or pulmonary, renal, or liver
failure.1 In addition, patients older than 79 years had been
excluded4 or had rarely been recruited in these trials. In
NASCET only 14% of all randomized patients were 75
years or older, and in ECST only 6% were 75 years or
older.1,6 However, older patients with symptomatic or
asymptomatic high-grade CAD are typically seen in every-
day clinical practice, which stresses the need to study this
patient population more actively.
In the past few years carotid angioplasty and stenting
(CAS) has increasingly been used as an alternative to CEA
for treatment of carotid stenosis. Although current data
from large randomized trials that directly compared CAS
with CEA are scarce and controversial,7-9 several single-
center studies have indicated that CAS can be performed
with acceptable complications rates.10 Because CAS has the
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and surgical incisions, the risk-benefit ratio may be greatest
in patients at high risk and elderly patients. Although
favorable CAS results have been reported in subgroups of
patients at high risk with severe concomitant diseases,11-15
advanced age was a significant predictor of periprocedural
deficits after unprotected CAS in one of the largest single-
center studies of CAS to date.14 Considering that reanalysis
of the large surgical trials shows that the benefit from
surgery for symptomatic carotid stenosis is greatest in pa-
tients aged 75 and older, due to a low rate of perioperative
complications,16 the question arises as to whether CAS is
indeed an attractive alternative to CEA in this subgroup of
patients. Therefore the objective of this study was to di-
rectly compare the complication rates within 30 days asso-
ciated with either protected CAS or CEA in a homoge-
neous population of patients aged 75 years and older.
SUBJECTS AND METHODS
Patients. From June 2001 to April 2004, 53 patients
aged 75 years and older with high-grade carotid stenosis
(70%, according to ECST criteria3) underwent CAS after
a prospective protocol approved by our institutional ethics
review board after giving informed consent. All patients
received detailed information about potential risks and
benefits, and the investigational nature of the procedure.
Patients with known allergies to aspirin or clopidogrel,
or to contrast media, or with total carotid occlusion, dis-
abling stroke, arteriovenous malformation, intracerebral
tumor, a diagnosis of dementia limiting informed consent,
cerebral hemorrhage in the past months, severe intracranial
stenosis, severe renal insufficiency, or evolving myocardial
infarction or stroke were excluded.
The surgical cohort comprised 110 patients aged 75
years or older who had undergone carotid surgery between
January 1997 and December 2001, before the widespread
introduction of CAS at our institution. This period was
chosen to exclude any potential bias toward CAS. As part of
an investigational registry at our hospital, data for the CAS
group were gathered prospectively, whereas data for the
surgical cohort were obtained in a retrospective, systematic
analysis of all hospital charts and medical records.
It is a policy of our hospital that principally all patients
with symptomatic or asymptomatic carotid stenosis are first
admitted to the Department of Neurology and are rou-
tinely seen after CEA or CAS. Therefore all surgical and
endovascular patients underwent preoperative and postop-
erative neurologic evaluation within the department. Be-
cause self-reported complication rates of vascular surgeons
may underestimate the frequency of complications,17,18
any patient who had been admitted to the Department of
Vascular Surgery directly to undergo an additional surgical
procedure along with CEA was excluded from the analysis.
With increasing personal experience and in line with 2
recent publications19,20 the selection criteria for the CAS
group were modified during the course of the study. Pa-
tients with long and multiple carotid artery stenoses, severe
peripheral vascular disease precluding femoral artery access,or with extremely tortuous carotid artery anatomy were
excluded.
In all patients the diagnosis of high-grade carotid artery
stenosis was made with carotid duplex ultrasound scanning
with a combination of direct and indirect criteria and the
presence and extent of intrastenotic and poststenotic tur-
bulent flow, according to the recommendations of the
Working Group of Vascular Diagnostics of the German
Society of Ultrasound in Medicine.21 In detail, as direct
criteria for local degree of stenosis, systolic peak flow veloc-
ity within the stenosis and the post-stenotic internal carotid
artery (ICA), diastolic peak flow velocity in the stenosis,
ICA—common carotid artery index, and prestenotic and
poststenotic frequency patterns were determined. The re-
sidual vessel lumen in the B-mode image and the color-
coded residual vessel area were documented. As indirect
criteria, flow characteristics of the supratrochlear artery and
pulsatility of the common carotid artery were taken into
account. As a key feature, stenosis 70% or greater was
diagnosed if peak systolic velocity exceeded 200 cm/s. In
all patients in the CEA group the presence of ICA stenosis
70% or greater according to ECST criteria was confirmed
angiographically before the surgical procedure and in all
patients in the CAS group during the stent procedure.
CAS. In all patients CAS was performed with a stan-
dardized protocol.22 At least 3 days before the procedure,
patients received orally administered aspirin (100 mg/d)
and clopidogrel (75 mg/d). Patients taking hypertensive
medications received their morning dose before stenting;
additional doses were withheld until after the procedure,
and were then given if necessary.
All stenting procedures were performed under anesthe-
siologic standby with continuous control of heart fre-
quency, blood pressure, and partial arterial oxygen tension
(PaO2). Before balloon inflation in each patient 0.5 mg of
atropine was administered intravenously as prophylaxis
against reflex bradycardia or asystole. All patients received
oxygen through a nasal tube (5 L/min) to reach greater
than 95% oxygen saturation. Except in 1 patient, all proce-
dures were performed with the patient under conscious
sedation.
Cerebral angiography (Biplanar Neurostar, Siemens)
was focused on the stent preselected carotid artery. After
acquisition of appropriate diagnostic images and measure-
ment of the stenosis according to ECST criteria a loading
dose of heparin (70-100 U/kg body weight) was adminis-
tered intravenously to obtain activated clotting time of 2.0
to 2.5 times baseline, corresponding to greater than 250
seconds. During the stenting procedure hourly boluses of
heparin (1000 units) followed. Glycoprotein IIb or IIIa
antagonists were not used.
In all patients filter-type embolic protection devices
were used during CAS. According to physician preference
and commercial availability, 2 different filter-type cerebral
protection devices (Mednova Neuroshield; Johnson &
Johnson—Cordis Angioguard Filter) were used in this
study.
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7F guiding catheter into the distal common carotid artery
the stenosis was crossed with a 0.014-inch guide wire,
placing the tip in the intracranial portion of the ICA at least
4 cm above the lesion. With the guide wire across the
stenosis the filter-type cerebral protection systems were
advanced across the target lesion and deployed in the distal
ICA. An angiogram was obtained to document device
placement distal to the target lesion and to document
blood flow through the filter device. The filter guide wire
was then used to deliver the balloon and the stent delivery
catheters. After filter opening, predilation with coronary
angioplasty balloons was performed in most cases, and
subsequently appropriately sized self-expandable stents
(Johnson & Johnson—Cordis Smart/Precise; Boston Sci-
entific Wallstent) were implanted. After stent placement a
second dilation was performed. To establish whether the
filter had become occluded with a large embolic volume
load and to confirm that the final dilatation of the stenotic
segment was adequate a completion angiogram was ob-
tained. Intracranial vessels were also imaged to avert unde-
tected compromise of the intracranial circulation from
thromboembolic events. At the end of the procedure a
retrieval sheath was advanced, and the filter was closed and
removed from the artery. Visual inspection of the filter was
performed at the end of each procedure to evaluate the
macroscopic presence of material. Formal histopathologic
analysis of all filters with macroscopically visible plaque
debris was not performed.
After the stent procedure heparin administration was
stopped, and all patients were transferred to the neurointen-
sive care unit for overnight observation. Heart rate and respi-
ratory rate were monitored continuously. Blood pressure was
monitored hourly with an automated cuff-inflation sphygmo-
manometer. Clopidogrel was continued for 6 weeks, and
aspirin was given indefinitely. To document patency of the
stent an ultrasound follow-up study was obtained routinely 1
or 2 days after CAS in all patients.
Surgical procedure. Experienced senior vascular sur-
geons performed all operations, with the patient under gen-
eral anesthesia. In most cases eversion endarterectomy was
performed, and in most patients intraoperative shunts were
used. Intraoperative transcranial Doppler ultrasound moni-
toring and imaging procedures were not carried out. All
patients had undergone independent neurologic examination
before surgery, in the wake-up room after the operation, 48
hours after surgery, and at discharge, andwere followed up for
at least 6 months after surgery. To document patency of the
treated artery an ultrasound follow-up study was performed
routinely 5 to 7 days after CEA in all patients.
Definitions of perioperative and peri-interventional
complication rates. Perioperative or peri-interventional
complication rates within 30 days were defined according
to criteria set forth in the large trials.1,2
Minor stroke was any new neurologic deficit, either
ocular or cerebral, that persisted for more than 24 hours
and increased the National Institutes of Health (NIH)
stroke scale less than 3 points.Major stroke was any new neurologic deficit that per-
sisted after 30 days and increased the NIH stroke scale by
more than 3 points.
Fatal stroke was death attributed to any ischemic or
hemorrhagic stroke.
Myocardial infarction was occurrence of a new Q-wave
in 2 or more leads; presence of elevated creatine kinase
(CK) or CK, myocardial bound (CKMB); or CK elevation
greater than twice the upper limit of normal in the presence
of elevated CKMB.
Inasmuch as transient ischemic attacks (TIAs) are sel-
dom diagnosed in surgical patients perioperatively, because
of anesthesia, this outcomemeasure was not included in the
analysis.
Data collection. In each patient careful history taking
and precise neurologic examination including the NIH
Stroke scale was performed by a stroke neurologist. In
patients with symptomatic ICA stenosis, symptoms and
timing of cerebral ischemic events and date and time of
symptom resolution in the case of TIAs were recorded.
Diagnosis of a hemispheric TIA was made on the basis of
the classic definition of a transient focal neurologic dysfunc-
tion of presumed ischemic cerebrovascular cause lasting less
than 24 hours. The classification of symptomatic or asymp-
tomatic carotid stenosis was based on the criteria set forth
in the large trials.1,2,23
In all patients the following cerebrovascular risk factors
were recorded: hypertension, diabetes mellitus, hyperlipid-
emia, smoking (current or within the previous year), periph-
eral vascular disease, and previous TIA or stroke. Hyperten-
sion was defined as occurring when systolic blood pressure
exceeded160mmHgordiastolic bloodpressure exceeded95
mmHg, or in the presence of antihypertensive drugs. Diabe-
tes was defined as previously diagnosed insulin-dependent or
non-insulin-dependent diabetes mellitus, and hyperlipidemia
as cholesterol concentration greater than 220 mg/dL or in
the presence of lipid-lowering drugs. In addition, the follow-
ing comorbid conditions, which would have led to exclusion
from the NASCET trial,1 were determined in each patient:
previous ipsilateral CEA; coronary artery disease; previous
coronary bypass; valvular heart disease; cardiac arrhythmia;
pulmonary, renal, or liver failure; unstable congestive heart
failure; unstable angina; intracranial atherosclerosisworse than
cervical lesion; and cancer with life expectancy less than 5
years.
All patients underwent systematic examination, ultra-
sound scanning, chest radiography, and electrocardiogra-
phy, and laboratory studies included complete blood cell
count, blood chemistry, lipid profiles, and coagulation
abnormalities. In some patients, additional thorough car-
diac investigation included transthoracic and transesopha-
geal echocardiography.
Statistical analysis. For comparison of categorical
data 2-tailed 2 statistics with Yates correction and univar-
iate Fisher exact test were used. The Fisher exact test was
used when the predicted contingency table cell values were
less than 5. P  .05 was considered statistically significant.
, tran
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The total study population consisted of 53 patients
in the CAS group and 110 patients in the CEA group.
Demographic characteristics for each treatment group
are summarized in Table I. The proportion of patients
who received treatment of symptomatic (60%) and
asymptomatic (40%) carotid stenosis was comparable
in both procedural groups. The presence of risk factors
for atherosclerosis and comorbid conditions was also
similar. In each group hypertension and hyperlipidemia
were the most frequent vascular risk factors, followed by
diabetes mellitus and cigarette smoking. The median
time from the last event to CAS (21 days, range 5-120
days) or CEA (20 days, range 4-130 days) in patients
with symptomatic disease was comparable.
In all patients in the CAS group placement of a cerebral
protection device was technically successful. Moreover, it
was possible to position a stent at the lesion site in all
patients. Macroscopically visible particles were retrieved in
27 of 53 (51%) of the CAS filter-type protection devices.
An ultrasound follow-up study documented patency of the
reconstructed artery after either CAS or CEA in all patients.
Periprocedural neurologic deficits occurring within 30
days in both treatment groups are summarized in Table II.
In neither group was there fatal stroke or myocardial infarc-
tion. All strokes were ipsilateral to the treated artery. In the
CAS group there were 4 minor strokes (7.5%) and 2 major
strokes (3.8%) (combined stroke rate, 11.3%). All strokes
occurred immediately or within the first 6 hours after
stenting. Two strokes, 1 major and 1 minor, were directly
related to use of cerebral protection devices. In 1 patient a
Table I. Baseline characteristics of patients according to t
Age (y)
Median
Range 7
Sex
Male
Female
Symptomatic disease
Previous stroke
Hemispheric TIA
Retinal TIA
Asymptomatic disease
Hypertension
Hyperlipidemia
Tobacco use, current or within previous year
Diabetes mellitus
Coronary artery disease
Previous coronary bypass
Peripheral vascular disease
Congestive heart failure
Contralateral ICA occlusion
Contralateral ICA stenosis 70%
CAS, Carotid angioplasty with stenting; CEA, carotid endarterectomy; TIAmajor stroke occurred after acute obstruction of the filter-type protection device with macroscopic visible debris. The
other patient sustained a minor stroke after difficult re-
trieval of the closed filter-type cerebral protection device
through the stent, which required repeated rotation of the
device.
In the CEA group there were no minor strokes (0%)
and 2 major strokes (1.8%). Both strokes were detected
immediately after surgery.
Although patients in the CEA group with symptomatic
disease had a higher stroke rate than patients in the CEA
group with asymptomatic disease (2.09% vs 0%; not signif-
icant [NS]), the overall complications rate was similar be-
tween patients in the CAS group with symptomatic or
asymptomatic disease (10% vs 13%; NS). The CAS group
had significantly more periprocedural strokes compared
with the CEA group (11.3% vs 1.8%; P  .05). While the
30-day major stroke rates between CAS and CEA groups
were comparable (3.8% vs 1.8%; P  .6), this effect was
mainly attributable to a significantly higher rate of minor
strokes in the CAS group (7.5% vs 0%; P  .05).
The frequency of other treatment-related complica-
tions within 30 days after either CAS or CEA are summa-
rized in Table III. While transient cranial neuropathies
were seen only in the surgical group (8% vs 0%; P  .05),
there was an unexpected trend toward higher rates of
(groin) hematoma requiring surgery or extended hospital
stay in the CAS group compared with the CEA group
(11.3% vs 4.5%; NS).
DISCUSSION
In this study we directly compared the complication
ent
CAS (N  53) CEA (N  110)
% n %
78
75–91
68 70 64
32 40 36
57 69 63
33 28 40
50 33 48
17 8 12
43 41 37
85 87 79
49 34 31
4 8 7
17 33 30
24 23 21
9 7 6
19 20 18
7 6 5
4 7 6
21 23 21
sient ischemic attack; ICA, internal carotid artery.reatm
n
78
5–90
36
17
30
10
15
5
23
45
26
2
9
13
5
10
4
2
11rates within 30 days associated with either protected CAS
, not s
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years or older. Although patients with several medical and
angiographic risk factors were included, the combined
overall 30-day stroke and death rates in the surgical group
of 2.9% in patients with symptomatic disease and 0% for
patients with asymptomatic disease were within the guide-
lines recommended by the American Heart Association.24
A low risk for perioperative stroke and death in patients
aged 75 years or older has also been found in a recent
subgroup analysis of the NASCET data.16 On the basis of
high risk for ipsilateral ischemic stroke if treated medically
and low surgical risk, this analysis demonstrated that only 3
patients aged 75 years or older would have to undergo
endarterectomy to prevent 1 ischemic stroke in 2 years.16
Likewise, a prediction model of the ECST data indicates
that increasing age is associated with greater benefit from
CEA.2 Taken together, these data indicate that CEA as an
invasive procedure performed with the patient under gen-
eral anesthesia is efficacious in older patients with symp-
tomatic and asymptomatic carotid stenosis. When the sur-
gery is performed by highly skilled surgeons, our results
support the notion that favorable results in older patients
can also be achieved outside the setting of randomized
trials.
For CAS, our combined overall stroke and death rate of
Table II. Periprocedural neurologic deficits within 30 day
CEA
n %
Patients with symptomatic disease 69 30
Minor stroke 0 0
Major stroke 2 2.9
Fatal stroke 0 0
Any stroke 2 2.9
Patients without symptomatic disease 41 23
Minor stroke 0 0
Major stroke 0 0
Fatal stroke 0 0
Any stroke 0 0
All patients 110 53
Minor stroke 0 0
Major stroke 2 1.8
Fatal stroke 0 0
Any stroke 2 1.8
CEA, Carotid endarterectomy; CAS, carotid angioplasty with stenting.
Table III. Frequency of other complications within 30 da
Craniel nerve palsy
Hematoma requiring surgery or extended hospital stay
Myocardial infarction
Transient renal dysfunction
CAS, Carotid angioplasty with stenting; CEA, carotid endarterectomy; NS10% and 13%, respectively, in patients aged 75 years orolder with symptomatic or asymptomatic disease, is higher
than previously published data in younger patients.10 Irre-
spective of age, a recent worldwide survey of 12,392 CAS
procedures, for example, found a 30-day procedure-related
mortality rate of 0.64%, major stroke rate of 1.20%, and
minor stroke rate of 2.1% (combined stroke and death rate,
3.94%).25 On the other hand, the high complication rates
observed in this study cannot be attributed to lack of
experience, because more than 300 CAS procedures have
been performed to date at our institution. Indeed, during
the study period patients younger than 75 years had a
periprocedural stroke and death rate of less than 3% at our
institution (unpublished data). Similar to our data, patients
aged 80 years and older had a 30-day stroke and death rate
of 16% in one of the largest single-center studies of unpro-
tected CAS to date.14 Our results are also comparable to a
combined stroke and death rate of 11.9% in patients aged
80 years and older found in the lead-in phase of the
ongoing Carotid Revascularization and Endarterectomy vs
Stent Trial (CREST).26 Although evidence is accumulating
that use of cerebral protection devices during CAS has the
potential to reduce thromboembolic complications,10,25
the high periprocedural complications of protected CAS
found in this study suggest that older patients might not
necessarily profit from the use of these devices. In support
CAS
OR 95% CI P%
6.6 0.0 0.0–2.3 .09
3.3 0.9 0.04–52.8 1.0
0
10 0.3 0.02–2.5 .2
8.7 0.0 0.0–2.9 .1
4.3 0.0 0.0–21.9 .3
0
13 0.0 0.0–1.3 .05
7.5 0.0 0.0–0.7 .05
3.8 0.5 0.03–6.7 .6
0
11.3 0.15 0.01–0.9 .05
ter CAS or CEA in patients aged 75 years or older
AS (N  53) CEA (N  110)
P% n %
0 9 8 .05
11.2 5 4.5 NS
0 0 0 NS
0 0 0 NS
ignificant.s
n
2
1
0
3
2
1
0
3
4
2
0
6ys af
C
n
0
6
0
0of this notion, the trend for higher stroke rates in older
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devices in the CREST trial.26 In fact, 2 procedural strokes
were directly related to the use of filter-type protection
devices in this study.
Compared with the CEA group, the 30-day stroke rate
was significantly higher in the CAS group. This result was
mainly attributable to a significantly higher rate of minor
strokes in the CAS group. Although not randomized pro-
spectively, both groups were comparable, and demographic
and angiographic characteristics cannot account for this
difference. Despite the small number of patients, this find-
ing indicates that the common practice of preferentially
submitting older patients to CAS is questionable, and
should be abandoned until the results of further random-
ized trials are available. Even in our patient population with
significant medical comorbid conditions, lack of severe
medical or increased neurologic complications periopera-
tively indicated that elderly patients undergoing CAS do
not necessarily profit from averting the risks of general
anesthesia. In line with this speculation, similar periopera-
tive complications were found in a large series of carotid
operations performed with the patient under regional or
general anesthesia.27
In addition to the small number of patients, we are
aware that our study has several other limitations. The
retrospective nature of our surgical data could have led to
underestimation of the true surgical complication rates,
whereas the prospective critical scrutiny for the new tech-
nique of CAS likely enabled detection of more adverse
events. It is unlikely that any disabling stroke was missed in
the surgical group, whereas we could have failed to notice a
minor stroke. On the other hand, it should be stressed that
the heterogeneity of patient populations, use of different
endovascular or surgical treatments, and dissimilar out-
come measures usually limit comparability of data across
institutions or trials. In contrast, our study groups were
comparable, a uniform outcome measure was applied, and
a board-certified neurologist evaluated all patients.
We focused primarily on the 30-day procedural risk for
stroke and death; thus the equally important issue of long-
term durability of each revascularization strategy in older
patients still needs to be addressed. Because of the relatively
small number of outcome events in each group, we did not
perform multivariate analysis of possible other clinical or
angiographic characteristics associated with increased risk
for stroke and death from either CEA or CAS.
CONCLUSION
Although CAS no doubt has several theoretical advan-
tages over CEA, our preliminary results clearly indicate that
the complication rates associated with CAS are significantly
higher than with CEA performed by highly skilled surgeons
in patients aged 75 years or older. In light of our local
experience and in good agreement with the low perioper-
ative complication rates of the large surgical trials, CEA
therefore remains the standard of treatment in older pa-
tients with high-grade symptomatic or asymptomatic ca-rotid stenosis. The relative role of CAS in older patients
must await the results of further randomized trials.
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